In this study, we show that the platelet surface expression of glycoprotein (GP) V is regulated by two independent mechanisms. While confirming that both thrombin and neutrophil elastase proteolyse GPV, we show that neutrophil cathepsin G, thrombin receptor activating peptide (TRAP), and a combination of ADP and epinephrine can each result in a decrease in the platelet surface expression of GPV by a nonproteolytic mechanism: a cytoskeletal-mediated redistribution of platelet surface GPV to the surface-connected canalicular system (SCCS). Four independent lines of evidence documented the nonproteolytic nature of this decrease in the platelet surface expression of GPV. First, flow cytometric studies showed that cathepsin G, TRAP, and ADP/epinephrine decreased the platelet surface expression of GPV without changing the total platelet content of GPV. Second, immunoelectron microscopy directly demonstrated translocation of GPV from the platelet surface to the SCCS. Third, the cathepsin G-, TRAP-, and ADPlepinephrine-induced decreases in platelet surface GPV were fully reversible. Fourth, cytochalasin B, an inhibitor of actin polymerization, completely inhibited the cathepsin G-, TRAP-, and ADPlepinephrine-induced decreases in platelet surface GPV. The cytoskeletal-mediated redistribution of GPV occurred in a whole blood milieu and at physiologic temperatures (37°C) and extracellular calcium concentrations (2 mmol/L). This study also defines the diverse effects on GPV, GPlb, and GPlX of multiple important platelet agonists. Cathepsin G proteolysed platelet surface GPlbru, but redistributed platelet surface GPlX and GPV to the SCCS. Thrombin proteo-LYCOPROTEIN (GP) Ib, GPIX, and GPV have recently been reported to form a noncovalent complex in the platelet surface membrane.' GPIb consists of an a chain disulfide-linked to a 0 chain.'." GPIba (molecular GPIbp (M, 24 kD), GPIX (M, 18 kD), and GPV (M, 82 kD) 0006-497//96/8704-0007$3.00/0 1396 lysed platelet surface GPV, but redistributed platelet surface GPlb and GPlX to the SCCS. Both TRAP and ADP/epinephrine redistributed platelet surface GPlb, GPIX, and GPV t o the SCCS. Elastase proteolysed platelet surface GPlbru and GPV, but, unlike the other agonists tested, neither proteolysed nor redistributed platelet surface GPIX. The experiments with TRAP showed that activation of the seven-transmembrane domain thrombin receptor can result in translocation of GPlb, GPIX, and GPV to the SCCS independently of the GPlb-mediated pathway of thrombin-induced platelet activation. This study also provides t w o additional lines of support for the recent report that GPV is noncovalently complexed with GPlb and GPlX in the platelet surface membrane. First, although only the GPlba subunit of this putative complex is known to be directly linked to the platelet cytoskeleton via actin-binding protein, cytochalasin B inhibited the ADP/epinephrine-, cathepsin G-, and TRAP-induced decrease in platelet surface GPV. Second, triple labeling flow cytometric experiments showed that, on each individual platelet, the ADPlepinaphrine-induced decrease and subsequent return of the platelet surface expression of GPV occurred simultaneously with the decrease and subsequent return of the platelet surface expression of GPlb. In summary, the platelet surface expression of GPV is regulated by t w o independent mechanisms: proteolysis and a reversible, cytoskeletal-mediated redistribution to the SCCS.
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CD42a, and CD42d, re~pectively.~.~ GPIba, GPIbP, GPIX, and GPV are all deficient in the Bernard-Soulier syndrome, an inherited platelet function defect.' Approximately 25,000, 25,000, and 1 1,000 copies of GPIba, GPIX, and GPV, respectively, are exposed on the surface of each resting platelet, 1 .10.1 I The amino terminal domain of GPIba contains a binding site for von Willebrand factor that mediates the shear-dependent adhesion of platelets to the subendothelium of damaged blood vessel walls."4 The amino terminal domain of GPIba also contains a binding site for thromGPIba is directly linked to the platelet cytoskeleton via actin-binding pr~tein.".'~ The specific functions of GPIbP, GPIX, and GPV are unknown, although phosphorylation of GPIbP may play a role in the regulation of actin polymerization."
Platelet surface GPIba can be proteolysed by neutrophil cathepsin neutrophil elastase,21.22 and calcium-dependent protease,23 or translocated via a cytoskeletal-mediated mechanism to the surface-connected canalicular system (SCCS) by
The platelet surface expression of GPIX can also be decreased via a cytoskeletal-mediated translocation to the SCCS by t h r~r n b i n "~~~ and cathepsin G." Platelet surface GPV can be proteolysed by thr~mbin,'.''.~~ neutrophil elastase," and calcium-dependent but it is not known whether the platelet surface expression of GPV can be decreased by a nonproteolytic mechanism. In this study, we show that the platelet surface expression of GPV can be regulated by two independent mechanisms: 
MATERIALS AND METHODS

Monoclonat anribodies (MoAbs).
The following murine MoAbs were obtained through the V" International Workshop on Human Leukocyte Differentiation Antigens, Boston, MA (1993; conference number, specificity, and supplier are in parentheses): SW16 (PO90, GPV-specific, Drs Albert E.G.&. von dem Borne and Piet W. Modderman, Amsterdam, The Netherlands); HIPT5 (P019, GPIba-specific, Dr Eric C-Y Lian, Miami, FL, and Dr Jin-Hsien Chen, San Jose, CA); HIPT2 (PO21, GPIba-specific, Drs Lian and Chen); AK2 (FQ24, GPIba, Dr Emmanuel J. Favaloro, Westmead, Australia); PHs206 (P073, GPIba-specific, Dr Qi-Hong Sun, Beijing, China); PHs132 (PO74, GPIba-specific, Dr Sun); PHs232 (PO77, GPIbaspecific, D r Sun); ES85 (PO79, GPIba-specific, Dr Sun); GR-P (5T-150, GPIX-specific, Dr Marin E. Ganido, Barcelona, Spain), and S12 (PO58, P-selectin-specific, Dr Rodger P. McEver, Oklahoma, In addition, the following three murine MoAbs were used (specificity and supplier in parentheses): 6D1 (GPIba-specific, Dr Barry S. Coller, Mount Sinai Medical Center, New York, NY)"; 7E3 (GPIIb-IIIa complex-specific, Dr C~l l e r )~' ; and Y2/5 1 (GPIIIa-specific, Dako Coy, Carpinteria, CA)."
For flow cytometry experiments, antibodies were biotinylated or conjugated with fluorescein isothiocyanate (FITC), as previously de~cribed,2'.~~ except for 7E3, which was directly conjugated to Rphycoerythrin (custom conjugation by Molecular Probes, Eugene, OR).
Flow cytometric analysis of platelet surface GPs on washed platelets. The method has been previously described. '3,20.34.35 The protocol was approved by the Committee for the Protection of Human Subjects in Research at the University of Massachusetts Medical Center. Peripheral blood was drawn from healthy adult volunteers who had not ingested aspirin or other antiplatelet drugs during the previous 10 days. The first 2 mL of blood drawn was discarded and then blood was drawn into a sodium citrate Vacutainer (Becton Dickinson, Rutherford, NJ), which does not result in platelet activat i~n .~~ After the addition to platelet-rich plasma (PRP) of citrate albumin wash buffer (128 mmol/L NaCl, 4.3 m m o K NaH2P0, .
HZO, 7.5 mmol/L Na2HP04, 4.8 mmoVL sodium citrate, 2.4 mmoV L citric acid, 0.35% bovine serum albumin, and 1 1 mmol/L glucose), pH 6.5, with 50 ng/mL prostaglandin (PG) El, washed platelets were prepared by centrifugation with final resuspension into modified Tyrode's buffer (137 mmol/L NaCI, 2.8 mmol/L KCI, 1 mmol/L MgCI2, 12 mmol/L NaHC03, 0.4 mmol/L Na2HP04, 0.35% bovine serum albumin, 10 mmol/L HEPES, and 5.5 mmol/L glucose), pH 7.4, as previously described.I3 In some experiments, as indicated, 2 mmol/L CaCI2, 3.2 mmoVL sodium citrate, or 2 mmol/L EDTA were added to the modified Tyrode's buffer. The washed platelets (75,0001pL) were then incubated at either 22°C or 37°C for either 10 or 15 minutes, as indicated, with various concentrations of an agonist: human a-thrombin (provided by Dr John W. Fenton 11, New York Department of Health, Albany, NY), TRAP (H-SFLLRNPNDKYEPF-OH; Calbiochem, La Jolla, CA), human neutrophil elastase (Calbiochem), human neutrophil cathepsin G (Calbiochem), a combination of ADP (BioData, Horsham, PA) and epinephrine (BioData), or control buffer. The samples were then fixed in 1% formaldehyde for 30 minutes at 22°C. In some experiments, before the addition of the agonist, the platelets were incubated at 22°C with or without 6 pmol/L cytochalasin B (Sigma, St Louis, 0~).30
MO; an inhibitor of actin polymerization3') for 15 minutes. After fixation, all samples were diluted 10-fold in modified Tyrode's buffer, pH 7.4. Samples were then incubated (at 22°C for 20 minutes) with a saturating concentration of a biotinylated MoAb (either the GPV-specific antibody SW16, the GPIb-specific antibody 6D1, or the GPM-specific antibody GR-P) and a near saturating concentration of fluorescein-conjugated MoAb YU51 (GPIIIa-specific), followed by an incubation (at 22°C for 15 minutes) with 30 @mL phycoerythrin-streptavidin (Jackson ImmunoResearch, West Grove, PA). Samples were then diluted 10-fold in modified Tyrode's buffer, pH 7.4, and stored at 4°C until flow cytometric analysis was performed (within 24 hours). Samples were analyzed in an EPICS Profile I1 flow cytometer (Coulter Cytometry, Hialeah, FL) equipped with a 500 mW argon laser (Cyonics, San Jose, CA) operated at 15 mW and a wavelength of 488 nm. The fluorescence of fluorescein and phycoexythnn was detected using 525 nm and 575 nm band pass filters, respectively. Flow cytometric analysis of platelet sufme GPs in whole blood. The method has been previously d e~c r i b e d .~,~~ There were no centrifugation, gel filtration, vortexing, or stimng steps that could artefactually activate platelets. Peripheral blood was drawn from healthy adult volunteers who had not ingested aspirin or other antiplatelet drugs during the previous 10 days. The first 2 mL of blood drawn was discarded and then blood was drawn into a sodium citrate Vacutainer. Within 15 minutes, the anticoagulated blood was diluted 1:l by volume in modified Tyrode's buffer (137 mmol/L NaCl, 2. In experiments designed to directly compare the kinetics of changes in platelet surface GPV to changes in platelet surface GPIb or P-selectin, the experiments were performed with the following modifications. (1) After the fixation and dilution steps, a saturating concentration of fluorescein-conjugated SW16, a saturating concentration of a biotinylated MoAb (either the GPIb-specific antibody 6D1 or the P-selectin-specific antibody 512). and a near saturating concentration of 7E3-phycoerythrin was added (15 minutes at 22"C), followed by streptavidin-red613 or streptavidin-red670 (GIBCO, Grand Island, NY; 15 minutes at 22°C). (2) Platelets were identified in whole blood by gating on both phycoerythrin positivity and their light scatter. (3) The platelets were then simultaneously analyzed for fluorescein and red613 (or red670) fluorescence.
Flow cytometric analysis of total platelet GPV, GPlb, and GPIX.
The total platelet content of GPV, GPIb, and GPIX was determined by flow cytometric analysis of permeabilized platelets, as previously d e~c r i b e d .~' .~~ Washed platelets (final concentration, 7S,OOo/pL) were incubated at 22°C for 20 minutes with either 1 U/mL a-thrombin, 25 pmol/L TRAP, a combination of 10 pmol/L ADP and S pmol/L epinephrine, IO pg/mL cathepsin G, 100.000 U/mL elastase, or no agonist. After fixation with 1% formaldehyde and a IO-fold dilution in modified Tyrode's buffer, pH 7.4, the platelets were incubated at 22°C for 20 minutes with a fluorescein-conjugated MoAb (the GPV-specific antibody SW16, the GPIb-specific antibody 6DI, or the GPIX-specific antibody GR-P; in 7-fold excess of the saturating concentrations for platelet surface GPV, GPIb, and GPIX, respectively) and 0.1% Triton X-100 (Sigma) in modified Tyrode's buffer, pH 7.4. After a further IO-fold dilution, platelet fluorescence was analyzed by flow cytometry. Background binding, obtained from parallel samples run with fluorescein-conjugated mouse IgG (rather than an MoAb), was subtracted from each test sample. Nonpermeabilized controls were prepared identically, except that Triton X-l00 was omitted.
Immunoelectron microscopy. This work was performed using the procedures developed by Hourdille et al. 24 In brief, venous blood was taken with informed consent from healthy male and female members of the hospital staff and anticoagulated with ACD, NIH formula A (1 part anticoagulant to 6 parts blood). PRP was prepared by centrifugation at 120g for I O minutes at room temperature. PGE, at 100 nmol/L (Sigma), apyrase at 25 pg/rnL (Sigma), and ACD-A ( I v01 to 9 v01 PRP) were then added. Unless stated otherwise, platelets were washed as previously de~cribed.'~ They were resus- or SO pmol/L TRAP-14-mer (Neosystem. Strasbourg, France) for 10 minutes at 37°C without stirring and fixed after the addition of an equal volume of cacodylate buffer, pH 7.2, containing 2% (wt/vol) paraformaldehyde and 0.1% (vol/vol) glutaraldehyde (Fluka AG, Buchs, Switzerland). Control incubations were performed in the absence of agonist. The fixed platelets were sedimented and washed before being infused with 2.3 mol/L sucrose, as previously described.'* After freezing in liquid nitrogen, blocks were cut using an Ultracut E Ultramicrotome attached to an FC 4E low temperature sectioning system (Reichert-Jung, Vienna, Austria). Ultrathin sections were mounted on collodium-coated nickel grids. Labeling of GPV was performed by incubating sections with MoAb SW16 at a dilution of 11SOO (vol/vol). Labeling of GPlb was performed with a mixture of 7 GPIba-specific murine MoAbs: HIE'T2. HIPTS, AK-2, PHS132, PHS206, PHS232, and ES8S (see above). A mixture of antibodies was chosen because a recent report suggested that a single MoAb to GPIb stains thrombin-stimulated platelets less well than a polyclonal antibody to the GPIba subunit.?' The dilution of each MoAb (purified IgG or ascites) in the mixture was determined by the saturating concentration of its binding to platelets, as determined by flow cytometry. Incubation of the sections with the mixture of MoAbs was performed by floating the grids on drops of antibody-containing solution. After washing, the grids were then floated onto drops of a solution containing goat antimouse IgG antibody adsorbed onto 5-nm gold particles (1:lOO dilution; AuroProbe EM GAM G5; Amersham, Les Ulis, Paris, France). An amplified labeling procedure was used in selected experiments with SW16. This consisted of first incubating the sections with biotin-labeled antimouse IgG used at a 1:30 dilution (Amersham), followed by a I : 100 dilution of streptavidin adsorbed onto 5-nm gold particles (Amersham). Sections were stained by uranyl acetate and protected by a film of methylcellulose before being observed at 80 kV in a Philips EM 201 electron microscope (Philips Ltd, Eindoven, The Netherlands). For GPV, gold particles were quantified on the plasma membrane and within the SCCS by visual counting on photographs of whole sections of 20 unstimulated and TRAP-14-mer activated platelets (magnification X 90,000). Results are given as the percentage of particles within each membrane system. ,
RESULTS
Efects of difSerent agonists on the platelet surface expression of GPV, as determined by flow cytometry. Thrombin, TRAP, neutrophil elastase, and neutrophil cathepsin G all resulted in a concentration-dependent decrease in the platelet surface expression of GPV (Fig 1) . However, the maximal decrease in the platelet surface expression of GPV was greater with thrombin and elastase than with TRAP and cathepsin G (Fig 1) .
Effect of different agonists on the total platelet content of GPV, as determined by flow cytometry. The above data suggested that the mechanism of the thrombin-and elastaseinduced decrease in the platelet surface expression of GPV may be different from the mechanism of the TRAP-and cathepsin G-induced decrease in the platelet surface expression of GPV. We therefore compared the effects of these different agonists on the total platelet content of GPV and platelet surface GPV, as defined by MoAb SW16 in a flow cytometric analysis of permeabilized and nonpermeabilized platelets (Fig 2A and B) . The thrombin-and elastase-induced decreases in platelet surface GPV (Fig 2A) were associated with a marked decrease in the total platelet content of GPV (Fig 2B) , consistent with the proteolysis of GPV that has previously been reported with these
In contrast, the TRAP-and cathepsin G-induced decreases in platelet surface GPV (Fig 2A) were not associated with any decrease in the total platelet content of GPV (Fig 2B) . In addition, the combination of ADP and epinephrine resulted in a decrease in the platelet surface expression of GPV (Fig 2A) that was not associated with a significant decrease in the total platelet content of GPV (Fig 2B) . These data suggested that the TRAP-, cathepsin G-, and ADP/epinephrine-induced decreases in platelet surface GPV were not the result of proteolysis.
In parallel experiments, we compared the effects of these agonists on the total platelet content and surface expression of GPIb, as defined by MoAb 6D1 (Fig 2C and D) . Thrombin, TRAP, ADP/epinephrine, cathepsin G, and elastase all decreased the platelet surface expression of GPIb, but the decreases were most pronounced with cathepsin G and elastase (Fig 2C) . Cathepsin G and elastase both resulted in a decrease in the total platelet content of GPIb, whereas thrombin, TRAP, and ADP/epinephrine did not (Fig 2D) . These data are consistent with previous evidence that cathepsin G and elastase proteolyse GPIb, whereas thrombin, TRAP, and ADP/epinephrine do not.'9-'2.25.27.4"
In addition, we compared the effects of these agonists on the total platelet content and surface expression of GPK, as defined by MoAb GR-P (Fig 2E and F) . Thrombin, TRAP, ADP/epinephrine, and cathepsin G all markedly decreased the platelet surface expression of GP=, whereas elastase e l a s t a s e (ku/rnL) cathepsin G (ra/rnL> had no effect (Fig 2E) . However, none of these agonists decreased the total platelet content of GPIX (Fig 2F) , showing that the decrease in platelet surface GPIX was not the result of proteolysis of GPM.
Effects of thrombin and TRAP on the platelet distribution of GPV, as determined by immuno-electron microscopy. To further understand the two pathways of decreased platelet surface GPV, the effects of thrombin and TRAP on the platelet distribution of GPV and, for comparison, GPIb were analyzed by immuno-electron microscopy ( Figs 3,4, and 5) . In unstimulated platelets, labeling with the anti-GPV MoAb SW16 was fairly evenly distributed over the entire plasma membrane (Fig 3a and b) . This labeling was less dense than was seen with a mixture of 7 anti-GPIb MoAbs (Fig 3c) . This difference was due to (1) the series of epitopes recognized by the mixture of anti-GPIb antibodies and (2) the fact that platelets have a lower number of GPV molecules than of GPIb molecules on their surface.' In fact, to optimally visualize the distribution of GPV, we regularly used an enhanced staining procedure involving the use of biotin-labeled second antibody, in turn located by streptavidin conjugated to gold particles. Additional staining was seen on the SCCS with the antibodies to both GPV and GPIb, with part of the SCCS labeled and other channels of the SCCS devoid of staining. Staining for GPV is shown for two platelets (Fig 3a and b) , the second of which (Fig 3b) has an abundant SCCS and an increased staining with SW16 Overall, our findings suggest heterogeneity in the distribution of both GPV and GPIb in the SCCS of unstimulated platelets. No significant labeling of the granule membranes was observed for either GPIb or GPV.
After platelet activation with thrombin, there were considerable modifications in the distributions of the glycoproteins, as shown in Fig 4. As compared with unstimulated platelets (Fig 3a and b) , thrombin resulted in a marked decrease in total staining of GPV, with only the occasional gold particle seen in the inner part of the platelet (Fig 4a) . This occasional labeling found inside the platelet could signify either (1) the continued presence of a small intraplatelet pool of GPV or (2) that a small amount of GPV was translocated from the plasma membrane to the membranes of the SCCS before proteolysis occurred. The effect of thrombin on GPIb (Fig  4b) was different from GPV (Fig 4a) . As compared with unstimulated platelets (Fig 3c) , thrombin resulted in a marked decrease in staining for GPIb on the plasma membrane but a marked increase in staining for GPIb along the membranes of the SCCS (Fig 4b) . These results, obtained with a mixture of MoAbs, therefore confirmed the previously described thrombin-induced translocation of the GPIb-IX complex to the SCCS. 24 After activation with 50 pmolL TRAP for 10 minutes, the platelets lost their discoid shape and appeared degranu- (Fig 5) . However, unlike native thrombin, stimulation of platelets with TRAP resulted in dilatation of the SCCS (Fig 5) , as previously de~cribed.~' TRAP resulted in a decrease in platelet surface staining by both the anti-GPV (Fig   5a) and the anti-GPIb MoAbs (Fig Sb) . In contrast to the effect of thrombin on GPV (Fig 4a) , but similar to the effects of both thrombin and TRAP on GPIb (Figs 4b and Sb), TRAP resulted in much of the GPV being located on the membranes of the SCCS (Fig 5a) .
The proportion of GPV staining on the plasma membrane and on the membranes of the SCCS was quantitatively evaluated before and after TRAP stimulation. The percentage of Effects of different agonists on the platelet surface expression and total platelet content of GPV, GPlb, and GPIX, as determined by flow cytometric analysis of nonpermeabilized and permeabilized platelets. Washed platelets were incubated (at 22°C for 10 minutes) with either 1 U/mL thrombin, 25 pmoI/L TRAP, a combination of 10 pmol/L ADP and 5 pmol/L epinephrine, 10 pg/mL neutrophil cathepsin G, 100,000 U/mL neutrophil elastase, or no agonist (buffer only). After fixation and dilution, the platelets were incubated (at 22°C for 20 minutes) with fluorescein-conjugated MoAb SW16 (GPV-specific, A and B), 6D1 (GPlb-specific, C and Dl, or GR-P (GPIX-specific, E and F) in the presence (B, D, and gold particles on the surface of unstimulated platelets was 58.8% ? 13.5% (mean -C SD, n = 20). After stimulation with 50 pmol/L TRAP for 10 minutes at 37"C, the percentage of gold particles on the platelet surface was 30.4% t-10.2%, representing a 48.3% decrease.
Overall, these results show that platelet activation can result in translocation of GPV (as previously described for GPIbZ4) from the platelet surface to the membranes of the SCCS, but, for this translocation to be observed, the platelets must be stimulated in the absence of GPV proteolysis. (Because MoAb SW16 recognizes an epitope on the portion of GPV that is proteolysed by thrombin [GPV,.,],' these experi- 
ments do not provide information as to whether or not the nonproteolysed portion of GPV [GPVR] is translocated to the SCCS.)
Role of actin polymerization in the decrease in platelet surface GPV. To examine the role of actin polymerization in the decrease in platelet surface GPV, experiments were performed with 6 pmoIL cytochalasin B, an inhibitor of actin p~lymerization.~' The cathepsin G-induced decrease in the platelet surface expression of GPV was completely inhibited by cytochalasin B (Fig 6) . Similar results were obtained with TRAP and the combination of ADP and epinephrine (data not shown). These data suggest that the cathepsin G-, TRAP-, and ADP/epinephrine-induced decrease in platelet surface GPV was via a cytoskeletal mechanism involving actin polymerization, rather than via proteolysis. In contrast, the thrombin-induced decrease in the platelet surface expression of GPV was only slightly inhibited by cytochalasin B (Fig 6) . Similar results were obtained with elastase (data not shown). These results are consistent with our immuno-electron microscopy findings that the thrombininduced decrease in platelet surface GPV was largely mediated by proteolysis, but that a small amount of GPV was, via a cytoskeletal-mediated mechanism, translocated from the plasma membrane to the membranes of the SCCS. . '' . . . Effects of temperature and extracellular calcium on the cytoskeletal-mediated decrease in platelet surface GPV.
We next examined the effects of temperature and extracellular calcium on the cytoskeletal-mediated decrease in platelet surface GPV (Fig 7) . The cathepsin G-induced decrease in platelet surface GPV was more pronounced at the physiologic temperature of 37°C than at 22°C (Fig 7, compare E  through H with A through D) . The cathepsin G-induced decrease in platelet surface GPV at a physiologic Ca2+ concentration (2 mmol/L, Fig 7D and H) was slightly more pronounced than in the presence of chelating agents (3.2 mmol/L citrate [ Fig 7B and F] or 2 mmoVL EDTA [ Fig 7C  and G] ), but was not significantly different from experiments performed in the absence of both Ca2' and chelating agents (Fig 7A and E) . Similarly, at physiologic temperatures (37°C) and calcium concentrations (2 mmoVL) there was an extensive thrombin-induced translocation of GPIb and GPIX to the SCCS and thrombin-induced proteolysis of GPV (data not shown).
Reversibility of the cytoskeletal-mediated decrease in platelet surface GPV. To examine the possibility that the cytoskeletal-mediated decrease in platelet surface GPV was reversible, experiments were performed with TRAP and the combination of ADP and epinephrine (Fig 8) . These experiments showed that the decrease in the platelet surface expression of GPV was maximal approximately 4 minutes after the addition of the agonist, but this was followed by a timedependent return in the platelet surface expression of GPV (Fig 8) . By 60 minutes after the addition of the agonist, there was an almost complete return in the platelet surface expression of GPV (Fig 8) . The lack of change in forward light scatter (an indication of platelet size) showed that the return in the platelet surface expression of GPV was not an artefact of platelet aggregation (data not shown). Examination of individual histograms showed that the loss and restoration of the platelet surface expression of GPV was not confined to a distinct subpopulation of platelets. Because the experiments examining reversibility were performed in a whole blood system, these data also show that, in addition to washed platelets (Figs 1 through 7) , the decrease in platelet surface GPV occurs in whole blood. Kinetics of the reversible cytoskeletal-mediated decrease in platelet surface GPV compared with the kinetics of degranulation. To compare the kinetics of the ADP/epinephrine-induced changes in the platelet surface expression of GPV with the kinetics of degranulation, as determined by the platelet surface expression of the a granule protein Pselectin, triple-labeling experiments were performed in whole blood. The binding of two MoAbs (the GPV-specific antibody SW16 and the P-selectin-specific antibody S12) was simultaneously analyzed on individual platelets in whole blood by the use of two fluorophores (fluorescein and red613). In this set of experiments, platelets were identified in whole blood by gating on a third fluorophore (phycoerythrin directly conjugated to the GPIIb-IIIa-specific MoAb 7E3), as well as by their characteristic light scatter. These triple-labeling experiments showed that, on each individual platelet, degranulation was complete within 1.5 minutes, whereas the decrease in the platelet surface expression of GPV was not complete until approximately 4 minutes after exposure to ADP and epinephrine. In contrast to the reversibility of the decrease in the platelet surface expression of GPV, the increase in the platelet surface expression of Pselectin was not reversible (data not shown).
Comparative kinetics of the reversible cytoskeletal-mediated decreases in platelet surface GPV and GPIb. In other triple-labeling experiments in whole blood, we used the GPV-specific MoAb SW 16, the GPIb-specific MoAb 6D 1, and, as a platelet identifier, the GPIIb-IIIa-specific MoAb 7E3. These experiments showed that, on each individual platelet, the TRAP-induced decrease and subsequent return of the platelet surface expression of GPV occurred simultaneously with the decrease and subsequent return of the platelet surface expression of GPIb (Fig 9) . DISCUSSION neutrophil elastase," and calcium-dependent p r~t e a s e~' .~~ are known to proteolyse platelet surface GPV. In this study, we show that neutrophil cathepsin G, TRAP, and a combination of ADP and epinephrine can each result in a decrease in the platelet surface expression of GPV by a nonproteolytic mechanism: a cytoskeletal-mediated redistribution of platelet surface GPV to the SCCS. Four independent lines of evidence documented the nonproteolytic nature of the decrease in the platelet surface expression of GPV. First, flow cytometric studies showed that cathepsin G, TRAP, and ADPIepinephrine decreased the platelet surface expression of GPV without changing the total platelet content of GPV. Second, immunoelectron microscopy directly showed translocation of GPV from the platelet surface to the SCCS. Third, cytochalasin B, an inhibitor of actin polymerization," completely inhibited the cathepsin G-, TRAP-, and ADP/epinephrine-induced decreases in platelet surface GPV. Fourth, the cathepsin C-, TRAP-, and ADP/ epinephrine-induced decreases in platelet surface GPV were fully reversible. Thrombin activates platelets by cleavage of its seventransmembrane domain receptor to yield a new N-terminus that then interacts with the receptor as a tethered ligand.4z
In this study, we compared the effects of native thrombin with the effects of a 14 amino acid TRAP that corresponds to the new N-terminus of the receptor.43 The differing results obtained with native thrombin (GPV proteolysis) and TRAP (GPV translocation via a cytoskeletal-mediated mechanism) suggest that GPV can be translocated from the platelet surface to the membranes of the SCCS, but, for the process to be observed, platelets need to be stimulated in the absence of GPV proteolysis. Consistent with these findings, translocation was observed with cathepsin G and ADP/epinephrine, which do not proteolyse GPV, but translocation was not observed with elastase, which proteolyses GPV. Because these studies were performed with MoAb SW16, which recognizes an epitope on the portion of GPV that is proteolysed by thrombin (GPVfl),' an unanswered question is whether or not the nonproteolysed portion of GPV (GPVn) is translocated to the SCCS. The answer to this question would depend, at least in part, on the effect of GPV proteolysis on the attachment of GPVn to GPIb-IX. This study defines the diverse effects on GPV, GPIb, and GPIX of multiple important platelet agonists. Neutrophil cathepsin G proteolyses platelet surface GPIba, but redistributes platelet surface GPIX and GPV to the SCCS . Thrombin proteolyses platelet surface GPV, but redistributes platelet surface GPIb and GPIX to the SCCS. Both TRAP and ADP/ epinephrine redistribute platelet surface GPIb, GPIX, and GPV to the SCCS. Neutrophil elastase proteolyses platelet surface GPIba and GPV, but, unlike the other agonists tested, neither proteolyses nor redistributes platelet surface GPIX.
A GPIb-dependent pathway has been implicated in platelet activation by t h r~m b i n . '~,~ However, the present flow cytometric and immunoelectron microscopic data obtained with TRAP, which does not activate platelets via GPIb,"'34z show that translocation of GPIb, GPIX, and GPV to the SCCS can occur independently of the GPIb-mediated pathway of thrombin-induced platelet activation. The TRAP-induced The present findings provide two additional lines of support for the recent report that GPV is noncovalently complexed with GPIb and GPIX in the platelet surface membrane.' First, although only the GPIba subunit of this putative complex is known to be directly linked to the platelet cytoskeleton via actin-binding protein,16." cytochalasin B inhibited the ADP/epinephrine-, cathepsin G-, and TRAPinduced decrease in platelet surface GPV. Second, triplelabeling flow cytometric experiments showed that, on each individual platelet, the ADP/epinephrine-induced decrease and subsequent return of the platelet surface expression of GPV occurred simultaneously with the decrease and subsequent return of the platelet surface expression of GPIb. The latter result suggests, given that the resting platelet surface expresses approximately 25,000 copies each of GPIba and GPIX but only approximately 11,OOO copies of GPV,'slosll that either some GPIb-IX complexes are translocated without GPV or that GPV is attached to two or more copies of GPIb-IX in a macromolecular complex. In any event, the presence of a noncovalent complex between GPIb, GPIX, and GPV would explain the lack of each of these GPs in the BernardSoulier syndrome.' Two recent reports, published since the original submission of this manuscript, provide evidence for 1 r l H CALCIUM a direct interaction between GPV and GPIb-IX in melanoma4' and Chinese hamster ovary (CHO)& cell lines, both of which lack actin-binding protein.
Using two independent methods (quantitative immunoelectron microscopy and flow cytometry), we have identified an internal pool of GPV in unstimulated platelets. In unstimulated platelets, the total platelet content of GPV as compared with the platelet surface content of GPV was similar between the two methods, ie, approximately twofold greater by quantitative immuno-electron microscopy and 2.5-to 3-fold greater by flow cytometry (Fig 2B) . The lower total platelet content of GPV determined by immuno-electron microscopy as compared with flow cytometry was probably accounted for by one or more of three factors. First, the flow cytometric detection of increased binding of MoAbs SW16, 6D1, and GR-P after platelet permeabilization with 0.1 % Triton X-100 may reflect, in addition to an internal antigen pool, increased accessibility for antibody binding of a subpopulation of GPV, GPIb, and GPIX molecules in the platelet surface membrane. Second, Behnke and Bray4' reported that the area of platelet surface membranes increased from 18 pmz to 70 pm2 during spreading. However, published electron microscopic studies of ultrathin sections of resting platelets do not show evidence of such a large reservoir of membranes. This suggests the possibility that many membranes are compacted inside the cell and are not visualized MICHELSON ET AL expression of the GPIb-IX-V complex, in association with the activation-dependent increase in the platelet surface expression of the GPIIb-IIIa ~o m p l e x~~.~" and P-selectin (CD62P),5'.52 transforms platelets from a state favoring adhesion to damaged vessel walls (mediated by von Willebrand factor binding to the GPIb-IX-V to a state favoring platelet-to-platelet aggregation (mediated by the binding of fibrinogen and other ligands to the GPIIb-IIIa complex5") and platelet-to-leukocyte adhesion (mediated by P-sele~tin'~-~~).
Analogous to the situation with GPIb,35 an important practical implication of the presently described time-dependent loss and restoration of the platelet surface expression of GPV is that in a given in vitro or in vivo experiment, the results of measurements of the platelet surface expression of GPV may vary unless the time of analysis or fixation is kept constant. Nevertheless, decreased platelet surface expression of GPV could be a useful marker of platelet activation in clinical settings. In a recent study of strenuous exercise in normal volunteers, we showed that decreased binding of MoAb 6D1, directed against the GPIb subunit of the GPIb-IX-V complex, was a more sensitive marker of platelet activation during exercise than MoAbs directed against P-selectin (S12) or the GPIIb-IIIa complex (PAC1).56
In summary, this study shows that the platelet surface expression of GPV can be regulated by two independent by current immuno-electron microscopic procedures. Third, whereas the fluorescein-conjugated MoAbs used in the flow cytometric method can gain easier access to their antigens (because fluorescein is a small molecule), immuno-electron microscopic staining decreases with increasing size of the gold particles conjugated to the antibody!8 For example, the use of 10-nm instead of 5-nm gold particles coated with antiIgG abruptly decreased platelet staining with antibodies to GPIb (P. Nurden, unpublished results). Extrapolation of this finding would suggest that some epitopes are not visualized by immuno-electron microscopy even with the 5-nm gold particles used in this study. In this study, there was heterogeneity in the distribution of both GPV and GPIb in the SCCS of unstimulated platelets. The SCCS of unstimulated platelets that were devoid of staining therefore reflected either a lower concentration of GPIb-IX-V and/or reduced accessibility of the epitopes recognized by the antibodies.
In this study, we show that the cytoskeletal-mediated redistribution of GPV can occur in a whole blood milieu and at physiologic temperatures (37°C) and extracellular calcium concentrations (2 mmol/L). Nevertheless, the biologic significance of these findings awaits characterization of the function of GPV. Recently, in cotransfection experiments in a melanoma cell line, Meyer and Fox4' showed that the presence of GPV augments the level of expression of the GPIBIX complex thereby increasing the binding capacity of these cells for von Willebrand factor. The presently described activation-dependent decrease in the platelet surface 
